Identification and evaluation of immune and targeted therapies for acral melanoma

Active Project Grant Awarded Last action

Award ID
HT9425261E240
Recipient
Awarding agency
Obligated
$1,349,148

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 5% complete
Place of performance
Philadelphia, PA 19107, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded Thomas Jefferson University $1.349 million on September 1, 2026, to identify and evaluate immune and targeted therapies for acral melanoma under the Military Medical Research and Development program (CFDA 12.420). The project runs through August 31, 2030, with performance at Thomas Jefferson's Philadelphia location. The award funds basic, applied, and advanced biomedical research intended to transform health care for service members and the American public through innovative medical solutions. Thomas Jefferson operates as Sidney Kimmel Medical College and houses the Sidney Kimmel Cancer Center, an NCI-designated comprehensive cancer center with research capability spanning cancer biology including melanoma.

Quick answers

Who received award HT9425261E240?

HT9425261E240 was awarded to Thomas Jefferson University by Defense Health Agency (Department of Defense) on September 1, 2026.

How much is award HT9425261E240 worth?

$1,349,148 has been obligated on HT9425261E240.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login